The Effect of Osteopathic Manipulative Techniques on Human Tear Composition
2026年8月22日 更新者:David Duriancik、Lake Erie College of Osteopathic Medicine
This is a pilot study to determine if osteopathic manipulation can alter the concentration of proteins and lipids in human tears.
研究概览
地位
邀请报名
研究类型
介入性
注册 (估计的)
30
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Pennsylvania
-
Erie、Pennsylvania、美国、16506
- Plaza 38 Medical Offices
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
是的
描述
Inclusion Criteria:
- Individuals older than 18 years of age at the time of enrollment
- Individuals that understand the study procedures and provide voluntary, informed consent
- Individuals willing and able to receive Osteopathic Manipulative Treatment
Exclusion Criteria:
- Individuals younger than 18 years of age
- Individuals who are pregnant or lactating
- Individuals with infection or inflammatory conditions
- Individuals physically unable to receive Osteopathic Manipulative Treatment
- Individuals with dental or oral infection or surgery within the preceding 30 days.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
假比较器:假
|
Sham protocol including holding of the occiput and thoracic area and cranial vault hold without interaction with the motion.
|
|
实验性的:Osteopathic Manipulative Treatment
Sequential Osteopathic Manipulative Treatment of suboccipital 4-step release, occipital mastoid suture release, and sphenopalatine ganglion release.
|
Sequential Osteopathic Manipulative Treatment of suboccipital 4-step release, occipital mastoid suture release, and sphenopalatine ganglion release.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Total tear protein concentration
大体时间:Baseline, 1 hour, and 1 week
|
Total protein concentration assessed using the bicinchoninic acid assay
|
Baseline, 1 hour, and 1 week
|
|
Secretory Immunoglobulin A Concentration
大体时间:Baseline, 1 hour, and 1 week
|
Human IgA, also known as human immunoglobulin A, is an antibody that is produced by the immune system in response to antigens.
It is the most abundant immunoglobulin in mucosal secretions, such as saliva, tears, and breast milk, and plays a key role in defense against pathogens at mucosal surfaces.
IgA works by binding to specific antigens and preventing them from entering the body's tissues.
It can also activate complement and promote phagocytosis by immune cells.
This protein typically represents 5-15% of total protein in tears.
|
Baseline, 1 hour, and 1 week
|
|
Tumor necrosis factor - alpha (TNFa) concentration
大体时间:Baseline, 1 hour, and 1 week
|
TNF alpha is a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily.
This cytokine is mainly secreted by macrophage and bind to its receptors, TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR.
TNF alpha is involved in the regulation of immune cells, cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation.
|
Baseline, 1 hour, and 1 week
|
|
Lipocalin-1 concentration
大体时间:Baseline, 1 hour, and 1 week
|
The protein encoded by this gene belongs to the lipocalin family.
Lipocalins are a group of extracellular proteins that are able to bind lipophiles by enclosure within their structures to minimize solvent contact.
This protein may bind hydrophobic ligands and inhibit cysteine proteinases.
This protein is also known as Tear Prealbumin and typically represents 15-25% of total protein in tears.
|
Baseline, 1 hour, and 1 week
|
|
secreted Phospholipase A2 (type IIA) concentration
大体时间:Baseline, 1 hour, and 1 week
|
Phospholipases A2 (PLA2s) make up a superfamily of enzymes that hydrolyze the ester bond of phosphoglycerides at the sn-2 position to release free fatty acid and lysophospholipids.
The sPLA2 responsible for the release of arachidonic acid in inflammation was believed to be Type IIA.
Although recently discovered isoforms of PLA2 clearly contribute to the release of arachidonic acid, sPLA2 (Type IIA) continues to be a protein of interest in the field of inflammation.
|
Baseline, 1 hour, and 1 week
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:David Duriancik, Ph.D.、Lake Erie College of Osteopathic Medicine
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年9月1日
初级完成 (估计的)
2026年10月2日
研究完成 (估计的)
2026年10月31日
研究注册日期
首次提交
2026年6月2日
首先提交符合 QC 标准的
2026年6月2日
首次发布 (实际的)
2026年6月8日
研究记录更新
最后更新发布 (实际的)
2026年8月25日
上次提交的符合 QC 标准的更新
2026年8月22日
最后验证
2026年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.